Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
Colorcon
Johnson and Johnson
Baxter

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR PONESIMOD


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ponesimod

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01093326 ↗ Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis Active, not recruiting Actelion Phase 2 2010-05-01 This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
NCT02068235 ↗ Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects Completed Actelion Phase 1 2014-08-01 This study consists of a single-dose pilot phase and a randomized, two-way crossover, single-dose main phase.The aim of this study is to evaluate the absolute bioavailability of the oral formulation (tablet) of ponesimod compared to an intravenous (i.v.) ponesimod formulation. Three subjects will be included in the pilot phase and 12 subjects in the main crossover phase.
NCT02136888 ↗ Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects Completed Actelion Phase 1 2011-08-01 The aim of this study is to demonstrate that therapeutic and supratherapeutic plasma exposures to ponesimod do not have an effect on cardiac repolarization exceeding the threshold of regulatory concern as measured by the QTc (interval from beginning of the Q wave until end of the T wave corrected for heart rate) interval duration after administration of multiple oral doses of 40 mg and 100 mg to healthy male and female subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ponesimod

Condition Name

Condition Name for Ponesimod
Intervention Trials
Multiple Sclerosis 4
Healthy 3
Chronic Graft Versus Host Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ponesimod
Intervention Trials
Sclerosis 4
Multiple Sclerosis 4
Multiple Sclerosis, Relapsing-Remitting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ponesimod

Trials by Country

Trials by Country for Ponesimod
Location Trials
United States 60
Canada 12
Mexico 6
Russian Federation 5
United Kingdom 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ponesimod
Location Trials
Indiana 6
California 5
Ohio 4
New York 4
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ponesimod

Clinical Trial Phase

Clinical Trial Phase for Ponesimod
Clinical Trial Phase Trials
Phase 3 3
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ponesimod
Clinical Trial Phase Trials
Completed 4
Active, not recruiting 2
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ponesimod

Sponsor Name

Sponsor Name for Ponesimod
Sponsor Trials
Actelion 7
Janssen Pharmaceutica N.V., Belgium 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ponesimod
Sponsor Trials
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
McKesson
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.